News Releases

May 11, 2020
Unum Therapeutics Reports First Quarter Financial Results and Provides Corporate Updates
CAMBRIDGE, Mass. , May 11, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020 , and provided corporate updates.
March 26, 2020
Unum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Updates
CAMBRIDGE, Mass. , March 26, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2019 , and provided
March 20, 2020
Unum Therapeutics Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital
CAMBRIDGE, Mass. , March 20, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced it has entered into a common stock purchase agreement for up to $25 million with Lincoln Park
March 2, 2020
Unum Therapeutics Implements Strategic Restructuring to Prioritize Efforts on BOXR1030 for the Treatment of Solid Tumor Cancers
BOXR1030 is a GPC3-targeted CAR T cell incorporating the novel GOT2 transgene designed to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism Investigational new drug (IND)-enabling studies are underway for BOXR1030 with plans to submit an application to the
January 29, 2020
Unum Therapeutics Provides Updates to its Phase 1 Trial of ACTR707 for HER2+ Solid Tumor Cancers
-Cohort 1 enrollment is complete with no dose-limiting toxicities observed- -Cohort 2 patient screening underway- -Safety and efficacy data from multiple dose cohorts expected during 2020- CAMBRIDGE, Mass. , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc.
The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Unum disavows any obligation to update the information contained in such press releases after the date of their issuance.